# A Study to Learn How Safe the Study Treatment BAY2701250 is, How it Affects the Body and How it Moves Into, Through and Out of the Body in Healthy Male Participants When a Single Amount is Given as an Injection Into the Vein (Intravenous Infusion) or Under the Skin (Subcutaneous Injection)

> **NCT06048120** · PHASE1 · COMPLETED · sponsor: **Bayer** · enrollment: 82 (actual)

## Conditions studied

- Pulmonary Hypertension Due to Left Heart Disease

## Interventions

- **DRUG:** BAY2701250 IV
- **DRUG:** Placebo IV
- **DRUG:** BAY2701250 SC
- **DRUG:** Placebo SC

## Key facts

- **NCT ID:** NCT06048120
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-15
- **Primary completion:** 2025-05-20
- **Final completion:** 2025-05-20
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2025-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06048120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06048120, "A Study to Learn How Safe the Study Treatment BAY2701250 is, How it Affects the Body and How it Moves Into, Through and Out of the Body in Healthy Male Participants When a Single Amount is Given as an Injection Into the Vein (Intravenous Infusion) or Under the Skin (Subcutaneous Injection)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06048120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*